
Release date: 2024-08-13 13:49:37 Article From: Lucius Laos Recommended: 307
Pemigatinib is indicated for adult patients with advanced, metastatic, or unresectable cholangiocarcinoma with FGFR2 fusion or rearrangement confirmed by testing.
Pemigatinib is indicated for patients with cholangiocarcinoma that has metastasized (i.e., spread to other parts of the body) or is locally advanced, and whose condition is no longer treatable by surgery.
Patients treated with Pemigatinib require genetic testing to confirm the presence of fusions or other rearrangement variants in the FGFR2 (fibroblast growth factor receptor 2) gene. Pemigatinib can effectively inhibit the growth and spread of this type of tumor by inhibiting the activity of FGFR2.
Patients should pay attention to the following before treatment with Pemigatinib to achieve the best treatment results.
Before taking Pemigatinib, patients need genetic testing to confirm whether their tumors have variants in FGFR2 or other related genes.
Pemigatinib may cause a range of side effects such as diarrhea, nausea, fatigue, etc. Patients should pay close attention to their own reactions during the course of medication and inform their doctor if they have any discomfort or worsening symptoms.
Many other medications can interact with Pemigatinib, so people should tell their doctor about all medications they are taking, including prescription drugs, over-the-counter medications, and supplements, before taking them.
Patients with cholangiocarcinoma may have negative emotions such as fear and depression, which are not easy to treat and recover from the disease and need timely psychological counseling from the patient's family.
Patients with cholangiocarcinoma often have negative emotions such as fear, anxiety, and depression, and medical staff should provide emotional support to encourage patients to maintain a positive attitude.
To the extent permitted by the medical protection system, patients are informed of their medical conditions and examination results, and their doubts and worries are reduced. At the same time, the treatment plan, surgical process, and possible prognosis of cholangiocarcinoma are explained to patients, so that patients can face the disease rationally.
【Warm tips】When patients buy generic drugs, they should choose formal channels to ensure the quality and safety of the drugs. Avoid purchasing counterfeit products from informal sources.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:3502025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:5512024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:3362025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:3512025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:3262025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:3932025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:3262025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:3002025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com

Name: Lucius

Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643